We are live on ! Find out more
SEEL

Seelos Therapeutics, Inc. Common Stock
SEEL

Delisted

SEEL was delisted on the 15th of October, 2024.

Back to rankings

68 hedge funds and large institutions have $27.1M invested in Seelos Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 13 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

481% more call options, than puts

Call options by funds: $749K | Put options by funds: $129K

300% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 3

77% more capital invested

Capital invested by funds: $15.3M → $27.1M (+$11.7M)

13% more funds holding

Funds holding: 60 → 68 (+8)

15% less repeat investments, than reductions

Existing positions increased: 11 | Existing positions reduced: 13

Holders
68
Holders Change
+8
Holders Change %
+13.33%
% of All Funds
1.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
12
Increased
11
Reduced
13
Closed
3
Calls
$749K
Puts
$129K
Net Calls
+$620K
Net Calls Change
+$330K

Top Buyers

Rank Fund Capital Flow
1
WE
Wealth Effects
Massachusetts
+$604K
2
WP
Woodline Partners
California
+$517K
3
EWA
EP Wealth Advisors
California
+$173K
4
GJL
Gendell Jeffrey L
+$90.2K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$48.6K

Top Sellers

Rank Fund Capital Flow
1
Mirae Asset Global Investments
Mirae Asset Global Investments
South Korea
-$378K
2
Millennium Management
Millennium Management
New York
-$142K
3
AI
AdvisorShares Investments
Maryland
-$93.7K
4
MCM
MAI Capital Management
Ohio
-$69.4K
5
BAM
Belpointe Asset Management
Nevada
-$34.6K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
51
Fidelity Investments
Massachusetts
$15.8K +$6.94K +2 +200%
Victory Capital Management
52
Victory Capital Management
Texas
$15.5K – – –
JF
53
Jump Financial
Illinois
$14.2K +$10.4K +3 New
CAG
54
Curtis Advisory Group
California
$13.4K +$10.4K +3 New
First Manhattan
55
First Manhattan
New York
$13.4K – – –
ACI
56
Alpha Cubed Investments
California
$13.1K – – –
ACA
57
Aptus Capital Advisors
Alabama
$12.5K – – –
GWANC
58
Guardian Wealth Advisors (North Carolina)
North Carolina
$12.5K – – –
Osaic Holdings
59
Osaic Holdings
Arizona
$12.4K – – –
EWA
60
EP Wealth Advisors
California
$11.9K +$173K +50 +5,000%
TRCT
61
Tower Research Capital (TRC)
New York
$10.1K +$6.94K +2 New
NFSG
62
Newbridge Financial Services Group
Florida
$9.56K – – –
Bank of America
63
Bank of America
North Carolina
$4.99K – – –
HCM
64
Hollencrest Capital Management
California
$3.11K – – –
Northwestern Mutual Wealth Management
65
Northwestern Mutual Wealth Management
Wisconsin
$2.99K +$3.47K +1 New
UBS Group
66
UBS Group
Switzerland
$2.75K – – –
TWC
67
TD Waterhouse Canada
Ontario, Canada
$2.38K – – –
FIA
68
FNY Investment Advisers
New York
$2K – – –
Royal Bank of Canada
69
Royal Bank of Canada
Ontario, Canada
$2K – – –
VWM
70
Venturi Wealth Management
Texas
$1.91K – – –
IA
71
IFP Advisors
Florida
$1.42K – – –
WIM
72
Westside Investment Management
California
$1.2K – – –
BCWM
73
Bartlett & Co Wealth Management
Ohio
$1.2K – – –
National Bank of Canada
74
National Bank of Canada
Quebec, Canada
$1.19K – – –
PA
75
Parallel Advisors
California
$1.01K – – –
1 2
3
4

SEEL Hedge Fund Activity: Q2 2023 in Review

68 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Seelos Therapeutics, Inc. Common Stock (SEEL) for Q2 2023, worth a combined $27.1M — up 77% from $15.3M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new SEEL positions and 3 closed out — a net gain of 9 holders — while 11 added to existing stakes and 13 trimmed.

The largest buyer was Wealth Effects, adding an estimated $604K. The largest seller was Mirae Asset Global Investments, cutting an estimated $378K.

  • 68 institutional investors held Seelos Therapeutics, Inc. Common Stock (SEEL) as of Q2 2023, up from 60 in Q1 2023.
  • Funds reported $27.1M of Seelos Therapeutics, Inc. Common Stock stock for Q2 2023, up 77% quarter-over-quarter.
  • 12 funds opened new Seelos Therapeutics, Inc. Common Stock positions in Q2 2023 and 3 closed out, a net change of +9 holders.
  • The largest Seelos Therapeutics, Inc. Common Stock buyer in Q2 2023 was Wealth Effects, an estimated $604K added.
  • The largest Seelos Therapeutics, Inc. Common Stock seller in Q2 2023 was Mirae Asset Global Investments, an estimated $378K sold.

Based on aggregated 13F filings for Q2 2023.